KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Leases (2020 - 2025)

Historic Current Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Q3 2025 value amounting to $601000.0.

  • Aquestive Therapeutics' Current Leases rose 2468.88% to $601000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $601000.0, marking a year-over-year increase of 2468.88%. This contributed to the annual value of $510000.0 for FY2024, which is 3076.92% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Current Leases is $601000.0, which was up 2468.88% from $570000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' Current Leases' 5-year high stood at $926000.0 during Q1 2022, with a 5-year trough of $255000.0 in Q4 2022.
  • In the last 5 years, Aquestive Therapeutics' Current Leases had a median value of $540000.0 in 2025 and averaged $595421.1.
  • Its Current Leases has fluctuated over the past 5 years, first tumbled by 7163.52% in 2022, then skyrocketed by 5294.12% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Current Leases (Quarter) stood at $899000.0 in 2021, then plummeted by 71.64% to $255000.0 in 2022, then surged by 52.94% to $390000.0 in 2023, then soared by 30.77% to $510000.0 in 2024, then grew by 17.84% to $601000.0 in 2025.
  • Its Current Leases was $601000.0 in Q3 2025, compared to $570000.0 in Q2 2025 and $540000.0 in Q1 2025.